You Have Been Invited!
Sophia Kamran, MD
Sophia C. Kamran, MD, is a Radiation Oncologist at the Massachusetts General Hospital and an Assistant Professor of Radiation Oncology at Harvard Medical School. She is the Director of Diversity, Equity, and Inclusion in the Department of Radiation Oncology at Massachusetts General Hospital and an Associate Member of the Broad Institute of MIT and Harvard. Dr. Kamran’s clinical interest is in genitourinary cancer care with a focus on harnessing computational/bioinformatics approaches to discover genomic and molecular predictors of response to radiation and characterize mechanisms of resistance. Her goal is to design clinical trials investigating genomically-guided radiation therapy to deliver optimal doses in combination with appropriate systemic therapy for improved outcomes. Her separate research effort focuses on dissecting translational science in diverse populations, ensuring that these populations are not left behind in the fields of translational and personalized oncology. Dr. Kamran has several professional membership affiliations with organizations such as the American Society for Radiation Oncology, the American Urological Association, the Accreditation Council for Graduate Medical Education, the Radiation Research Society, the American Society for Clinical Oncology, the American Board of Radiology, the American Association for Cancer Research, the Massachusetts General Hospital Cancer Center Equity Council, and the Massachusetts Prostate Cancer Coalition. Nationally, she serves on ASTRO's Workforce Diversity Committee and ASCO’s Equity, Diversity, and Inclusion Committee. She was selected as a 2021 ASTRO Leadership Pipeline Program Protégé for her work on diversity, equity, and inclusion efforts, and she is a current NRG Health Equity Fellow. She is a recipient of a 2023 Harvard Medical School Harold Amos Faculty Diversity Award, an award given to individuals who have demonstrated a significant commitment to enhancing diversity and inclusion at HMS and its teaching hospitals. She is the 2024 Co-Chair of the Renal & Rare Tumors Track for the ASCO Genitourinary Cancers Symposium and was the Organizing Chair for the 2023 Coffey-Holden Prostate Cancer Academy Meeting, sponsored by the Prostate Cancer Foundation. She is on the NCI P01 Massachusetts General Hospital Internal Steering Committee, serves on the Editorial Board for Clinical Genitourinary Cancer and is a GU Associate Section Editor for Practical Radiation Oncology. Her work has been published in many high-quality journals, including The New England Journal of Medicine, Clinical Cancer Research, JAMA Oncology, European Urology, and others. Dr. Kamran holds a bachelor’s degree in Biological Engineering from the Massachusetts Institute of Technology, which she attended as a Gates Millennium Scholar. She received her medical degree cum laude from Harvard Medical School. During her medical training, she completed a Howard Hughes Medical Student Research Fellowship. She completed a transitional year internship at Memorial Sloan Kettering Cancer Center, and residency training at the Harvard Radiation Oncology Program.
Advancements in Treating Early-Stage Biochemical Recurrence in Hormone-Sensitive Prostate Cancer
This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC). Prostate cancer is the most common solid cancer in men worldwide. Most men are diagnosed as having localized disease because of the widespread use of prostate-specific antigen screening. Men diagnosed as having clinically localized prostate cancer have multiple disease management options, including active surveillance, surgery, or radiotherapy. After local therapy, the treatment of early-stage non-metastatic biochemical recurrence (BCR) in hormone-sensitive (or castrate-sensitive) prostate cancer (HSPC) is not clear cut and options are limited. Treatment options also differ based on whether the patient has a low-risk or high-risk prostate cancer.
Self Study
-
Advancements in Treating Early-Stage Biochemical Recurrence in Hormone-Sensitive Prostate Cancer: Baseline Assessment
The following questions are designed to assess your knowledge and practice of patients with nmHSPC.
-
Module 1: Risk stratification of patients with biochemical recurrence after primary therapy for early hormone-sensitive prostate cancer
This module will cover risk stratification in patients who have had primary therapy and subsequent biochemical recurrence, with a focus on high- and very high-risk patients.
-
Module 2: Current and emerging treatments in nmHSPC after BCR
This module will cover the current and emerging treatments for non-metastatic hormone-sensitive prostate cancer (nmHSPC) following biochemical relapse (BCR).
-
Module 3: How initial localized PC treatment choice impacts later treatment options
This module will cover how initial treatment choice for localized prostate cancer (radical prostatectomy or radiotherapy) affects availability and efficacy of later treatment options.
-
Module 4: Shared clinical decision-making tools in early prostate cancer
This module will cover the use of clinical shared decision-making tools in early-stage prostate cancer.
-
Advancements in Treating Early-Stage Biochemical Recurrence in Hormone-Sensitive Prostate Cancer: Final Assessment
The following questions are designed to assess your gained knowledge and practice of patients with nmHSPC.
Live Group Discussions
-
Live Group Discussion 1
During this session, we will review the self-study modules and discuss approaches to treatment that offer optimal care to patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC).
-
Live Group Discussion 2
During this session, we will review the patient case and discuss treatment plans. Additionally, we will share our action plans and how this CME activity will shape our practice regarding patient care.
Group Challenge
Prostate Cancer Group Task: Theo's Case
This case follows a 68-year-old gentleman who is diagnosed with prostate cancer and, after initial treatment, eventually develops a biochemical recurrence. The group assignments will cover issues ranging from initial treatment to management of biochemic
My Action Plans
-
Your action plan in: non-metastatic hormone-sensitive prostate cancer
In light of the information reviewed and discussed during this program, please share an action plan that you will implement to improve the diagnosis and management for your patients with non-metastatic hormone-sensitive prostate cancer.
